Exploratory study of premenstrual symptoms and serotonin variability

Clayton, Anita H.; Keller, Adrienne; Leslie, Carine E.; Evans, Wyatt R.

doi:10.1007/s00737-005-0118-4

Cited by 15 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, γ-amino-butyric-acid (GABA) inhibition has been implicated in depression pathophysiology, differs between men and women, and can be modulated by progesterone and estrogen 48 , 49 . We have observed a significant reduction of the neurotransmitter serotonin and several neurotransmitter metabolic precursors (tyrosine, tryptophan, 3-methoxytyrosine, GABA, L-phenylalanine) which is consistent with previous research that demonstrates reduced mood enhancing neurotransmitter metabolite levels in the luteal phase, such as, 5-hydroxyindoleacetic acid (5-HIAA), the serotonin metabolite 50 (Table 1 , and Fig. 5 ).…”

Section: Discussionsupporting

confidence: 92%

Menstrual cycle rhythmicity: metabolic patterns in healthy women

Draper

Duisters

Weger

et al. 2018

Sci Rep

151

130

View full text Add to dashboard Cite

The menstrual cycle is an essential life rhythm governed by interacting levels of progesterone, estradiol, follicular stimulating, and luteinizing hormones. To study metabolic changes, biofluids were collected at four timepoints in the menstrual cycle from 34 healthy, premenopausal women. Serum hormones, urinary luteinizing hormone and self-reported menstrual cycle timing were used for a 5-phase cycle classification. Plasma and urine were analyzed using LC-MS and GC-MS for metabolomics and lipidomics; serum for clinical chemistries; and plasma for B vitamins using HPLC-FLD. Of 397 metabolites and micronutrients tested, 208 were significantly (p < 0.05) changed and 71 reached the FDR 0.20 threshold showing rhythmicity in neurotransmitter precursors, glutathione metabolism, the urea cycle, 4-pyridoxic acid, and 25-OH vitamin D. In total, 39 amino acids and derivatives and 18 lipid species decreased (FDR < 0.20) in the luteal phase, possibly indicative of an anabolic state during the progesterone peak and recovery during menstruation and the follicular phase. The reduced metabolite levels observed may represent a time of vulnerability to hormone related health issues such as PMS and PMDD, in the setting of a healthy, rhythmic state. These results provide a foundation for further research on cyclic differences in nutrient-related metabolites and may form the basis of novel nutrition strategies for women.

show abstract

Section: Discussionsupporting

confidence: 92%

Menstrual cycle rhythmicity: metabolic patterns in healthy women

Draper

Duisters

Weger

et al. 2018

Sci Rep

151

130

View full text Add to dashboard Cite

show abstract

“…65 Alternative hypotheses for the fast action of SSRIs in PMDD include enhanced function of 5-HT 2C receptors 66 and inhibition of the serotonin transporter with resulting decreased LH production. 67 It has also been hypothesized that the increase in ALLO after SSRI administration underlies the improvement in depressive symptoms of MDD in both sexes.…”

Section: Etiologymentioning

confidence: 99%

Premenstrual Dysphoric Disorder: Burden of Illness and Treatment Update

Pearlstein¹,

Steiner²

2012

FOC

103

View full text Add to dashboard Cite

291Five percent of menstruating women have severe premenstrual symptoms and impairment of functioning defined as premenstrual dysphoric disorder (PMDD). Clinically significant premenstrual symptoms occur in at least an additional 20% of menstruating women. The diagnosis of PMDD should be confirmed by prospective symptom charting over 2 menstrual cycles to confirm the timing of the symptoms and to rule out other diagnoses. The burden of illness of PMDD includes disruption of parenting and partner relationships and decreased productivity in work roles. In addition, women with PMDD have increased use of health care services such as clinician visits and increased use of prescription medications and over-the-counter preparations. The etiology of PMDD is multifactorial. In particular, dysregulation of the serotonin and allopregnanolone systems is implicated. Several effective treatment options exist, including serotonergic antidepressant medications and an oral contraceptive that contains ethinyl estradiol and drosperinone. In addition, other hormones that suppress ovulation, anxiolytics, cognitive therapy, chasteberry and calcium may be helpful.Cinq pour cent des femmes menstruées ont des symptômes prémenstruels sévères et une incapacité du fonctionnement appelée trouble dysphorique prémenstruel (TDPM). Au moins 20 % de femmes menstruées de plus ont des symptômes prémenstruels cliniquement significatifs. Il faut confirmer le diagnostic de TDPM en suivant les symptômes de façon prospective au cours de deux cycles menstruels afin de confirmer le moment de l'apparition des symptômes et d'exclure d'autres diagnostics. Le fardeau morbide imposé par le TDPM comprend la perturbation des relations avec les enfants et le partenaire et une baisse de productivité au travail. Les femmes atteintes de TDPM ont en outre recours davantage aux services de santé comme les visites aux cliniciens et prennent davantage de médicaments d'ordonnance et en vente libre. L'étiologie du TDPM est multifactorielle. La dysrégulation des systèmes de la sérotonine et de l'allopregnanolone en particulier est mise en cause. Il existe plus d'un traitement efficace possible, y compris des antidépresseurs sérotonin-ergiques et un contraceptif oral qui contient de l'éthinyloestradiol et de la drosperinone. D'autres hormones qui bloquent l'ovulation, des anxiolytiques, la thérapie cognitive, le gattilier (Vitex agnus castus) et le calcium peuvent en outre aider. Review Paper Examen critique DiagnosisAbout 80% of women report at least mild premenstrual symptoms, 20%-50% report moderate-to-severe premenstrual symptoms, and about 5% report severe symptoms for several days with impairment of functioning.

show abstract

“…26 Genes that have been suggested as possibly related include those that code for ␥-aminobutyric acid (GABA) and serotonin (5-HT) receptors. [31][32][33][34][35] Further evidence of the role of serotonin in the development of menstrual cycle-related symptoms is derived from studies that show selective serotonin reup- 28 One study 29 evaluated positron emission tomography and 5-HT1A receptor binding potential in women with PMDD and control subjects during the follicular and luteal phases.…”

Section: Etiologymentioning

confidence: 99%

Symptoms Related to the Menstrual Cycle: Diagnosis, Prevalence, and Treatment

Clayton

2008

Journal of Psychiatric Practice

View full text Add to dashboard Cite

Menstrual cycle-related symptoms are associated with the intrinsic hormonal fluctuations of the menstrual cycle. These symptoms can be physical, behavioral, or emotional and include problems such as dysmenorrhea, premenstrual syndrome (PMS), and premenstrual dysphoric disorder (PMDD). Because of the emotional and behavioral aspects of menstrual cycle-related symptoms, it is likely that clinical psychiatrists will encounter these symptoms in their daily practice and should therefore be familiar with their diagnosis, prevalence, etiology, and treatment. As many as 2.5 million women are affected by menstrual disorders each year, which can have a profound impact on their quality of life. Although a definitive etiology has yet to be established, fluctuations in estrogen and progesterone as well as genetic factors are thought to contribute to the occurrence of menstrual disorders. Current treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs) (for dysmenorrhea), lifestyle changes, selective serotonin reuptake inhibitors (SSRIs), and ovulation suppression (e.g., with oral contraceptives). Treatment with oral contraceptives (OCs), particularly extended or continuous use, may significantly reduce the incidence of menstrual cycle-related symptoms.

show abstract

Exploratory study of premenstrual symptoms and serotonin variability

Cited by 15 publications

References 30 publications

Menstrual cycle rhythmicity: metabolic patterns in healthy women

Menstrual cycle rhythmicity: metabolic patterns in healthy women

Premenstrual Dysphoric Disorder: Burden of Illness and Treatment Update

Symptoms Related to the Menstrual Cycle: Diagnosis, Prevalence, and Treatment

Contact Info

Product

Resources

About